Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Deepa Bhojwani(St. Jude Children's Research Hospital), Susan R. Rheingold(Children's Hospital of Philadelphia), Claudia Rössig(University Hospital Münster), Vilmarie Rodriguez(Mayo Clinic in Arizona), Elizabeth A. Raetz(NYU Langone Health), Nirali N. Shah(National Institutes of Health), Luciano Dalla‐Pozza(Children's Hospital at Westmead), Sarah Alexander(Hospital for Sick Children), Michel Zwaan(Erasmus MC), Aurélie Cabannes(Hôpital Saint-Louis), Richard Sposto(Children's Hospital of Los Angeles), Keith J. August(Children's Mercy Hospital), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Amrana Quereshi(Oxford University Hospitals NHS Trust), Jennifer L. McNeer, Maryalice Stetler‐Stevenson(National Cancer Institute), Maureen M. O’Brien(Cincinnati Children's Hospital Medical Center), Mignon L. Loh(Seattle Children's Hospital), Paul G. Schlegel(Universitätsklinikum Würzburg), Constance M. Yuan(National Cancer Institute)
Cited by 209
Related Papers
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934